Abrezekimab, a novel treatment , is attracting substantial excitement within the medical community as a likely option for managing a spectrum of immune-mediated diseases. This biologic agent works by specifically blocking a important pathway involved in inflammation , offering a new approach compared to traditional therapies. Initial clinical resea